A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Micro-Abstract A phase II randomized study of pemetrexed combined with cisplatin or carboplatin as first-line treatment for stage IIIB/IV non–small-cell lung cancer. Sixty-five patients were randomized to each arm. The results of the 6-month progression-free survival rate, median overall survival, a...

Full description

Saved in:
Bibliographic Details
Published inClinical lung cancer Vol. 14; no. 3; pp. 215 - 223
Main Authors Schuette, Wolfgang H.W, Gröschel, Andreas, Sebastian, Martin, Andreas, Stefan, Müller, Thomas, Schneller, Folker, Guetz, Sylvia, Eschbach, Corinna, Bohnet, Sabine, Leschinger, Monika I, Reck, Martin
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2013
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carboplatin - adverse effects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Cisplatin - administration & dosage
Cisplatin - adverse effects
Disease-Free Survival
Female
First-line treatment
Glutamates - administration & dosage
Glutamates - adverse effects
Guanine - administration & dosage
Guanine - adverse effects
Guanine - analogs & derivatives
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Male
Middle Aged
Neoplasm Metastasis
Nonsquamous histology
Pemetrexed
Platinum combinations
Pulmonary/Respiratory
Stage IIIB/IV non–small-cell lung cancer
First-line treatment
Stage IIIB/IV non–small-cell lung cancer
Nonsquamous histology
Platinum combinations
Pemetrexed
Online AccessGet full text

Cover

More Information
Summary:Micro-Abstract A phase II randomized study of pemetrexed combined with cisplatin or carboplatin as first-line treatment for stage IIIB/IV non–small-cell lung cancer. Sixty-five patients were randomized to each arm. The results of the 6-month progression-free survival rate, median overall survival, and safety analyses demonstrated efficacy and tolerability of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with advanced non–small-cell lung cancer.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2012.10.001